Hepatorenal syndrome
详细信息 查看全文
- 作者：Bimaljit Singh Sandhu MBBS ; MD…
- 刊名：Current Treatment Options in Gastroenterology
- 出版年：2005
- 出版时间：December 2005
- 年：2005
- 卷：8
- 期：6
- 页码：443-450
- 全文大小：
- 参考文献：1.Arroyo V, Gines P, Gerbes AL, et al.: Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996, 23: 164鈥?76. Details the diagnostic criteria, predictive factors, and outcome of HRSPubMed CrossRef
2.Follo A, Llovet JM, Navasa M, et al.: Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994, 20: 1495鈥?501.PubMed CrossRef
3.Cabrera J, Arroyo V, Ballesta AM, et al.: Aminoglycoside nephrotoxicity in cirrhosis. Value of urinary beta 2-microglobulin to discriminate functional renal failure from acute tubular damage. Gastroenterology 1982, 82: 97鈥?05.PubMed
4.Sherlock S, Walker JG, Senewiratne B, et al.: The complications of diuretic therapy in patients with cirrhosis. Ann N Y Acad Sci 1966, 139: 497鈥?05.PubMed CrossRef
5.Boyer TD, Zia P, Reynolds TB: Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease. Gastroenterology 1979, 77: 215鈥?22.PubMed
6.Newell GC: Cirrhotic glomerulonephritis: incidence, morphology, clinical features, and pathogenesis. Am J Kidney Dis 1987, 9: 183鈥?90.PubMed
7.Johnson RJ, Gretch DR, Yamabe H, et al.: Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993, 328: 465鈥?70.PubMed CrossRef
8.Lai KN, Li PK, Lui SF, et al.: Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med 1991, 324: 1457鈥?463.PubMed CrossRef
9.Schrier RW, Arroyo V, Bernardi M, et al.: Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988, 8: 1151鈥?157.PubMed CrossRef
10.Arroyo V, Bosch J, Mauri M, et al.: Renin, aldosterone and renal haemodynamics in cirrhosis with ascites. Eur J Clin Invest 1979, 9: 69鈥?3.PubMed CrossRef
11.Martin PY, Gines P, Schrier RW: Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998, 339: 533鈥?41.PubMed CrossRef
12.Ring-Larsen H, Hesse B, Henriksen JH, et al.: Sympathetic nervous activity and renal and systemic hemodynamics in cirrhosis: plasma norepinephrine concentration, hepatic extraction, and renal release. Hepatology 1982, 2: 304鈥?10.PubMed CrossRef
13.DiBona GF: Renal neural activity in hepatorenal syndrome. Kidney Int 1984, 25: 841鈥?53.PubMed
14.Uriz J, Gines P, Ortega R, et al.: Increased plasma levels of neuropeptide Y in hepatorenal syndrome. J Hepatol 2002, 36: 349鈥?55.PubMed CrossRef
15.Rimola A, Gavaler JS, Schade RR, et al.: Effects of renal impairment on liver transplantation. Gastroenterology 1987, 93: 148鈥?56.PubMed
16.Restuccia T, Ortega R, Guevara M, et al.: Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol 2004, 40: 140鈥?46.PubMed CrossRef
17.Runyon BA: Management of adult patients with ascites caused by cirrhosis. Hepatology 1998, 27: 264鈥?72.PubMed CrossRef
18.Cardenas A, Arroyo V: Hepatorenal syndrome. Ann Hepatol 2003, 2: 23鈥?9.PubMed
19.Gines P, Tito L, Arroyo V, et al.: Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988, 94: 1493鈥?502.PubMed
20.Gines P, Cardenas A, Arroyo V, et al.: Management of cirrhosis and ascites. N Engl J Med 2004, 350: 1646鈥?654.PubMed CrossRef
21.Baik SK, Jeong PH, Ji SW, et al.: Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison. Am J Gastroenterol 2005, 100: 631鈥?35.PubMed CrossRef
22.Villanueva C, Planella M, Aracil C, et al.: Hemodynamic effects of terlipressin and high somatostatin dose during acute variceal bleeding in nonresponders to the usual somatostatin dose. Am J Gastroenterol 2005, 100: 624鈥?30.PubMed CrossRef
23.D鈥橝mico G, Pietrosi G, Tarantino I, et al.: Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: a Cochrane meta-analysis. Gastroenterology 2003, 124: 1277鈥?291.PubMed CrossRef
24.Kiser TH, Fish DN, Obritsch MD, et al.: Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. Nephrol Dial Transplant 2005, 20: 1813鈥?820.PubMed CrossRef
25.Malay MB, Ashton JL, Dahl K, et al.: Heterogeneity of the vasoconstrictor effect of vasopressin in septic shock. Crit Care Med 2004, 32: 1327鈥?331.PubMed CrossRef
26.Uriz J, Gines P, Cardenas A, et al.: Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000, 33: 43鈥?8.PubMed CrossRef
27.Moreau R, Durand F, Poynard T, et al.: Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002, 122: 923鈥?30.PubMed CrossRef
28.Halimi C, Bonnard P, Bernard B, et al.: Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol 2002, 14: 153鈥?58.PubMed CrossRef
29.Hadengue A, Gadano A, Moreau R, et al.: Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998, 29: 565鈥?70.PubMed CrossRef
30.Ortega R, Gines P, Uriz J, et al.: Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002, 36: 941鈥?48.PubMed
31.Solanki P, Chawla A, Garg R, et al.: Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 2003, 18: 152鈥?56.PubMed CrossRef
32.Mulkay JP, Louis H, Donckier V, et al.: Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study. Acta Gastroenterol Belg 2001, 64: 15鈥?9.PubMed
33.Guevara M, Gines P, Fernandez-Esparrach G, et al.: Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998, 27: 35鈥?1.PubMed CrossRef
34.Gulberg V, Bilzer M, Gerbes AL: Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 1999, 30: 870鈥?75.PubMed CrossRef
35.Pomier-Layrargues G, Paquin SC, Hassoun Z, et al.: Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology 2003, 38: 238鈥?43.PubMed CrossRef
36.WongF, Pantea L, Sniderman K: Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004, 40: 55鈥?4. This study highlights the role of TIPS and vasoconstrictors in the treatment of HRS.PubMed CrossRef
37.Angeli P, Volpin R, Gerunda G, et al.: Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999, 29: 1690鈥?697.PubMed CrossRef
38.Lin SM, Lee CS, Kao PF: Low-dose dopamine infusion in cirrhosis with refractory ascites. Int J Clin Pract 1998, 52: 533鈥?36.PubMed
39.Bennett WM, Keeffe E, Melnyk C, et al.: Response to dopamine hydrochloride in the hepatorenal syndrome. Arch Intern Med 1975, 135: 964鈥?71.PubMed CrossRef
40.Durkin RJ, Winter SM: Reversal of hepatorenal syndrome with the combination of norepinephrine and dopamine. Crit Care Med 1995, 23: 202鈥?04.PubMed CrossRef
41.Gulberg V, Luppa P, Pauletzki J, et al.: [Successful conservative therapy of hepatorenal syndrome with vasopressin-1-receptor antagonist ornipressin]. Z Gastroenterol 1998, 36: 1053鈥?058.PubMed
42.Duvoux C, Zanditenas D, Hezode C, et al.: Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 2002, 36: 374鈥?80.PubMed CrossRef
43.Holt S, Goodier D, Marley R, et al.: Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet 1999, 353: 294鈥?95.PubMed CrossRef
44.Soper CP, Latif AB, Bending MR: Amelioration of hepatorenal syndrome with selective endothelin-A antagonist. Lancet 1996, 347: 1842鈥?843.PubMed CrossRef
45.Rossle M, Haag K, Ochs A, et al.: The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. N Engl J Med 1994, 330: 165鈥?71.PubMed CrossRef
46.Lake JR, Ring E, LaBerge J, et al.: Transjugular intrahepatic portacaval stent shunts in patients with renal insufficiency. Transplant Proc 1993, 25: 1766鈥?767.PubMed
47.Spahr L, Fenyves D, N鈥橤uyen VV, et al.: Improvement of hepatorenal syndrome by transjugular intrahepatic portosystemic shunt. Am J Gastroenterol 1995, 90: 1169鈥?171.PubMed
48.Sturgis TM: Hepatorenal syndrome: resolution after transjugular intrahepatic portosystemic shunt. J Clin Gastroenterol 1995, 20: 241鈥?43.PubMed CrossRef
49.Brensing KA, Textor J, Strunk H, et al.: Transjugular intrahepatic portosystemic stent-shunt for hepatorenal syndrome. Lancet 1997, 349: 697鈥?98.PubMed CrossRef
50.Guevara M, Gines P, Bandi JC, et al.: Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998, 28: 416鈥?22.PubMed CrossRef
51.Brensing KA, Textor J, Perz J, et al.: Long term outcome after transjugular intrahepatic portosystemic stentshunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000, 47: 288鈥?95. This study features the role of TIPS and vasoconstrictors in the treatment of HRS.PubMed CrossRef
52.Mitzner SR, Stange J, Klammt S, et al.: Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000, 6: 277鈥?86.PubMed CrossRef
53.Sort P, Navasa M, Arroyo V, et al.: Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999, 341: 403鈥?09.PubMed CrossRef
54.Akriviadis E, Botla R, Briggs W, et al.: Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119: 1637鈥?648.PubMed CrossRef
55.Gines P, Guevara M, Arroyo V, et al.: Hepatorenal syndrome. Lancet 2003, 362: 1819鈥?827.PubMed CrossRef
56.Gines A, Escorsell A, Gines P, et al.: Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993, 105: 229鈥?36. Defines the diagnostic criteria, predictive factors, and outcome of HRSPubMed
57.Colle I, Durand F, Pessione F, et al.: Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis. J Gastroenterol Hepatol 2002, 17: 882鈥?88.PubMed CrossRef - 作者单位：Bimaljit Singh Sandhu MBBS, MD (1)
Arun J. Sanyal MBBS, MD (1)
1. Division of Gastroenterology, Hepatology & Nutrition, VCU Medical Center, MCV Box 980341, 23298, Richmond, VA, USA - 刊物类别：Gastroenterology;
- 刊物主题：Gastroenterology;
- 出版者：Springer US
- ISSN：1534-309X
文摘